WEDNESDAY, Oct. 13, 2021 (HealthDay News) — Long-term marine omega-3 supplementation is associated with an increased risk for atrial fibrillation (AF), according to a study published online Oct. 6 in Circulation.

Baris Gencer, M.D., M.P.H., from Geneva University Hospitals in Switzerland, and colleagues conducted a systematic literature review to identify randomized controlled trials assessing the effects of marine omega-3 fatty acids supplementation on cardiovascular outcomes. The meta-analysis included seven trials (81,210 patients).

The researchers reported that nearly three-quarters of participants (72.6 percent) were enrolled in trials testing ≤1 g/day and 27.4 percent in trials testing >1 g/day of omega-3 fatty acids. The mean age of participants was 65 years, with 39 percent women and an average follow-up of 4.9 years. The meta-analysis showed the use of marine omega-3 fatty acid supplements was associated with an increased risk for AF (2,905; hazard ratio [HR], 1.25), with the risk higher in the trials testing >1 g/day (HR, 1.49) versus those testing ≤1 g/day (HR, 1.12). “Since the benefit of omega-3 fatty acids also appears to be dose dependent, the associated risk of AF should be balanced against the benefit on atherosclerotic cardiovascular outcomes,” the authors write.

For latest news and updates

Abstract/Full Text (subscription or payment may be required)

Copyright © 2021 HealthDay. All rights reserved.
healthday